Fishman Jay A Ltd. MI Lowers Stock Position in Pfizer Inc. $PFE

Fishman Jay A Ltd. MI trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 22.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 197,270 shares of the biopharmaceutical company’s stock after selling 55,687 shares during the period. Pfizer comprises 0.5% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 28th biggest holding. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $5,539,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Kepler Cheuvreux Suisse SA acquired a new position in shares of Pfizer during the 3rd quarter worth $16,613,000. Mackenzie Financial Corp increased its holdings in Pfizer by 119.6% during the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. increased its holdings in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Ameriprise Financial Inc. raised its position in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after acquiring an additional 5,978,927 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Pfizer in the third quarter valued at about $81,298,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.04 on Wednesday. The company has a market cap of $137.00 billion, a P/E ratio of 18.35 and a beta of 0.35. The business has a fifty day simple moving average of $25.51 and a 200-day simple moving average of $26.21. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the business posted $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being highlighted by multiple value-oriented articles as a cheap healthcare stock, with some analysts and commentators arguing the shares may offer upside at current levels for investors seeking income and defensive exposure. 2 Dirt Cheap Healthcare Stocks to Buy in July
• Positive Sentiment: Pfizer won FDA approval for IBRANCE in HER2-positive breast cancer, adding a fresh regulatory win and another potential use case for one of its key oncology drugs. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Cantor Fitzgerald reaffirmed a neutral rating but maintained a $27 price target, implying upside from current levels and signaling that Wall Street still sees valuation support. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Pfizer is drawing attention as a high-yield dividend stock, but several articles frame the yield as a sign of investor caution rather than a clear bullish catalyst. 2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them
• Neutral Sentiment: Analysts are still debating Pfizer’s long-term growth prospects versus peers like AstraZeneca, suggesting the market remains uncertain about the pace of future expansion. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Neutral Sentiment: Pfizer also received renewed scrutiny over its dividend sustainability, with some commentary warning investors to read the “fine print” on the payout. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think
• Negative Sentiment: Pfizer was downgraded to Hold, with analysts citing delayed pipeline catalysts, leadership changes, and reduced near-term re-rating potential. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
• Negative Sentiment: One market recap said Pfizer fell while the broader market rose, underscoring ongoing pressure tied to concerns about growth and sentiment. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why

Analyst Ratings Changes

A number of brokerages have recently weighed in on PFE. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $32.00 to $28.00 in a research note on Monday. Citigroup raised their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Guggenheim upped their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Finally, Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.59.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.